LabCorp Injects $2M into SynapDx for Autism Test Development | GenomeWeb

NEW YORK (GenomeWeb News) – Laboratory Corporation of America is investing $2 million in SynapDx to further its development of an autism spectrum disorder test.

The investment, announced today by SynapDx, follows a $6 million Series A1 funding round completed in December to support the Lexington, Mass.-based firm's clinical study in support of the ASD test, which is intended to help physicians identify children with ASD earlier than they can today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.